Indications |
Oral Allergic conditions Adult: 5 mg once daily. Child: ≥12 yr: 5 mg once daily; 6-11 yr: 2.5 mg; 1-5 yr: 1.25 mg; 6-11 mth: 1 mg. Doses to be taken once daily. Renal impairment: Initially, 5 mg every other day. Hepatic impairment: Initially, 5 mg every other day. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Severe renal or hepatic failure; children <6 mth, elderly, epilepsy, pregnancy and lactation. |
Adverse Reactions |
Headache, fatigue, somnolence, dizziness; nausea, dyspepsia; xerostomia, dysmenorrhoea; pharyngitis. |
Overdose Reactions |
Treatment is symptomatic and supportive. Standard measures to reduce absorption to be adopted. Haemodialysis unlikely to be useful. |
Mechanism of Actions |
Desloratadine is a long-acting, tricyclic, non-sedating, selective peripheral histamine H1-receptor antagonist which inhibits the release of pro-inflammatory mediators from human mast cells and basophils. Absorption: Peak plasma concentrations after 3 hr (oral). Distribution: Protein-binding: 82-87%. Metabolism: Hepatic; converted to 3-hydroxydesloratadine. Excretion: Via urine and faeces (as metabolites). |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store below 30°C. |
ATC Classification |
R06AX27 - desloratadine ; Belongs to the class of other antihistamines for systemic use. |
Storage |
Oral: Store below 30°C. |
Available As |
|
Desloratadine
Post Review about Desloratadine Click here to cancel reply.
Desloratadine Containing Brands
Desloratadine is used in following diseases
Drug - Drug Interactions of Desloratadine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.